A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: We conducted a phase 1, multicenter, open‐label, dose‐escalation study (TDM3569g) to assess the safety, tolerability, and pharmacokinetics of single‐agent trastuzumab emtansine (T‐DM1) administered weekly and once every 3 weeks in patients with HER2‐positive metastatic breast cancer previously treated with trastuzumab. The weekly dose results are described here. METHODS: Patients were administered escalating doses of T‐DM1 weekly, starting at 1.2 mg/kg. Additional patients were enrolled at the maximum tolerated dose (MTD) to better characterize tolerability and pharmacokinetics. RESULTS: Twenty‐eight patients received weekly T‐DM1, and the MTD was determined to be 2.4 mg/kg. In general, T‐DM1 was well tolerated, requiring few dose modifications or discontinuations because of adverse events (AEs). Grade ≥3 AEs were reported in 19 patients (67.9%); treatment‐related AEs occurred in 25 (89.3%) patients. Exposure to weekly T‐DM1 was dose‐proportional at ≥1.2 mg/kg, and accumulation of T‐DM1 and total trastuzumab was observed. Objective partial tumor responses were reported in 13 (46.4%) patients; the median duration of response was 18.6 months, and the 6‐month clinical benefit rate was 57.1%. CONCLUSION: The results suggest that a weekly dose of T‐DM1 2.4 mg/kg has antitumor activity and is well tolerated in patients with HER2‐positive metastatic breast cancer. Cancer 2012. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
van Geel, R., Wijdeven, M. A., Heesbeen, R., Verkade, J. M. M., Wasiel, A. A., van Berkel, S. S., & van Delft, F. L. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00224 · Cited by 279
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0064 · Cited by 276
Metadata
- Authors
- Beeram, M., Krop, I. E., Burris, H. A., Girish, S. R., Yu, W., Lu, M. W., Holden, S. N., & Modi, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-05-30
- Volume
- 118
- Issue
- 23
- Pages
- 5733-5740
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2056017799
- Cited by
- 103
- References
- 0
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer. https://app.cochat.ai/papers/10.1002/cncr.27622
- The paper
- Beeram, M., Krop, I. E., Burris, H. A., Girish, S. R., Yu, W., Lu, M. W., Holden, S. N., & Modi, S. (2012). A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer. Cancer. https://doi.org/10.1002/cncr.27622
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.